No Data
Sunshine Nuohe (688621.SH): Currently, stable synthesis of drugs such as Semaglutide and Tirzepatide has been achieved using solid-phase synthesis technology.
On December 23, Glonghui reported that Sunlight Novo Nordisk (688621.SH) stated on the investor interaction platform that its wholly-owned subsidiary Chengdu Novo Nordisk Shengtai Biotechnology Co., Ltd. has established a distinctive innovative research and development platform for peptide and peptide-like drugs, creating a unique model for innovative drug development. The company is currently able to stably synthesize drugs such as Semaglutide and Teriparatide using solid-phase synthesis technology, and in-depth research can be conducted based on market and business layout. Currently, the company is conducting a total of 6 clinical trial services for GLP-1 class innovative drugs, covering indications for weight loss and blood sugar control, which are in the clinical phase.
Sunshine Novo (688621.SH): As of now, the trend of new customers and Orders is good.
On December 23, Gelo Exchange reported that Sunshine Novo (688621.SH) disclosed its investor relations activity record showing that the integrated R&D service model of "preclinical + clinical" exhibits significant competitive advantages. This model can fully meet the diverse service needs of clients, thereby enhancing the success rate and efficiency of drug development. This advantage helps strengthen the company's ability to secure Orders. In the face of increasing competition within the Industry, the company has adopted a more proactive market expansion strategy by regularly communicating with clients for project planning to ensure precise alignment of R&D services. As of now, new clients and Orders have been developed.
Sunshine Novo (688621.SH): Currently, 12 Innovative Drugs have been included in the research and development reserve.
On December 19, Gelonghui reported that Sunshine Novo Nordisk (688621.SH) stated on the investor interaction platform that the company's main Business focuses on the field of drug research services. Due to the differing stages of research projects, their execution cycles vary. During the project advancement process, the company follows the principle of phased payment collection and recognizes revenue according to R&D progress or final delivery of outcomes. Therefore, the company's Business itself does not possess characteristics of quarterly cyclicality. Short-term market fluctuations do not truly reflect the intrinsic value of the enterprise. In recent years, the company has gradually increased its investment in the R&D field each year, especially in the area of Innovative Drugs research and development, through
Intense competition in CRO has reduced gross margin. Sunlight Nuohe is entering the animal health field to seek new growth points.
① Sunshine Nuohuo has experienced growth in revenue and net income in the first three quarters of this year compared to previous years, but intense competition in the industry has led to a decline in gross margin, and the chairman revealed that the company is increasing its investment in research and development. ② To seek new growth points, Sunshine Nuohuo is expanding its CRO business from the human pharmaceutical field to the animal health field by establishing subsidiaries, and has signed service orders with several medium and large animal pharmaceutical companies.
Sunshine Nuohuo (688621.SH): Has not yet entered the field of CDMO contract manufacturing services.
On November 19th, Guang Longhui reported that Sunshine Nuohuo (688621.SH) stated on the investor interaction platform that the products independently developed and reserved by the company are transferred before and after obtaining clinical trial approvals, and subsequent services are also locked in. Currently, the company has not entered the CDMO contract manufacturing service field, so this system does not have a significant impact on the company's operation. In addition, this type of draft for comments will go through a period of public consultation before formal issuance.
Sunshine Novo: Third Quarter Report 2024